Cellular and molecular chaperone fusion vaccines: targeting resistant cancer cell populations.
Cellular and molecular chaperone fusion vaccines: targeting resistant cancer cell populations.
复制标题
DOI：
10.3109/02656736.2013.792126
复制
发表时间：
2013-08
期刊：
影响因子：
--
通讯作者：
Murshid A
中科院分区：
文献类型：
--
作者：
Calderwood SK;Gong J;Stevenson MA;Murshid A
基于分子伴侣的疫苗为癌症治疗提供了许多优势。我们讨论了从肿瘤树突状细胞融合物中温和分离Hsp70制备的疫苗（Hsp70融合疫苗）的部署。该疫苗在触发特异性T细胞免疫和治疗荷瘤小鼠方面非常有效，并且与其他基于伴侣蛋白的分离物相比，该制剂保留了更多的肿瘤抗原。这种方法的另一个优点是肿瘤亚群可用于制备Hsp70融合疫苗。细胞融合疫苗是专门针对卵巢癌干细胞（CSC）中富集的耐药癌细胞和肿瘤细胞群而研制的。这些疫苗显示出对这些耐药卵巢癌群体触发T细胞免疫的增强能力。我们已经讨论了使用细胞和Hsp70融合疫苗方法治疗耐药癌细胞的潜力，以及将其与电离辐射或热疗联合使用以增强两种治疗形式的有效性。
Molecular chaperone-based vaccines offer a number of advantages for cancer treatment. We have discussed the deployment of a vaccine prepared by gentle isolation of Hsp70 from tumor dendritic cell fusions (Hsp70 fusion vaccine). The vaccine was highly effective in triggering specific T cell immunity and in the treatment of tumor bearing mice and the preparation was shown to retain an increased amount of tumor antigens compared to other chaperone-based isolates. This approach has the further advantage that tumor sub-populations could be used to prepare the Hsp70 fusion vaccine. Cellular fusion vaccines were made to specifically target drug resistant cancer cells and tumor cell populations enriched in ovarian cancer stem cells (CSC). Such vaccines showed enhanced capacity to trigger T cell immunity to these resistant ovarian carcinoma populations. We have discussed the potential of using the cellular and Hsp70 fusion vaccine approaches in therapy of treatment resistant cancer cells and its deployment in combination with ionizing radiation or hyperthermia to enhance the effectiveness of both forms of therapy.